The initiation of transcription in eukaryotes is regulated by a network of protein-protein interactions between sequencespecific transcription factors, their cofactors, and components of the general transcription machinery (reviewed in Refs. 1-5). One target of the site-specific transcriptional regulators is the general transcription factor TFIID, which is a multisubunit complex made up of the TATA box-binding protein and multiple TATA box-binding protein-associated factors (TAF II s).
The initiation of transcription in eukaryotes is regulated by a network of protein-protein interactions between sequencespecific transcription factors, their cofactors, and components of the general transcription machinery (reviewed in Refs. [1] [2] [3] [4] [5] . One target of the site-specific transcriptional regulators is the general transcription factor TFIID, which is a multisubunit complex made up of the TATA box-binding protein and multiple TATA box-binding protein-associated factors (TAF II s). 1 Previous in vitro studies have pointed to the role of TAF II s as coactivators that interact with and mediate activation by selected transcriptional regulators (reviewed in Refs. 6 -9) . In addition, TAF II s interact with core promoter elements and play a role in promoter recognition. hTAF II 250 also possesses enzymatic activities postulated to modulate chromatin structure and general transcription factor activity (10, 11) . The recent discovery of a subset of TAF II s shared by TFIID and chromatin remodeling complexes further points to multiple functions of TAF II s in regulating eukaryotic gene expression (reviewed in Refs. 12 and 13).
To determine contribution that TAF II s make to transcriptional activation, several studies have examined the interplay between transcriptional regulators and TAF II s. A number of TAF II s from Drosophila, yeast, and humans have been isolated and shown to interact with distinct activators in vitro (reviewed in Refs. 2 and 14) . However, the requirement of TAF II s in activated transcription remains controversial; for example, in vivo studies in yeast have indicated that TAF II s are not required for the transcription of all genes (15, 16) but that certain TAF II s are required for the transcription of genes critical for cell cycle regulation (16 -19) . Genome-wide expression profiling confirmed these findings; 16% of 6000 genes in the yeast genome were affected by the inactivation of yTAF II 145 (20) . Thus, TAF II s serve important functions for a subset of genes.
The involvement of human TAF II 130 in activator-TAF II interactions has been examined in detail. hTAF II 130 and/or its Drosophila homolog dTAF II 110 have been shown to interact with cellular transcriptional activators such as Sp1 (21, 22) , the cAMP-response element binding protein (CREB) (23, 24) , CCAAT-binding factor CBF (25) , as well as nuclear receptors, viral transcriptional regulators, and a transcriptional repressor (26 -33) . Sp1 and CREB interact with one or more of the four central glutamine-rich domains Q1-Q4 of hTAF II 130 as determined by in vitro binding and yeast two-hybrid assays (21, 23) . Analysis of the C-terminal and N-terminal deletion mutants of hTAF II 130 indicates that the Sp1 and CREB activation domains target distinct regions of the central glutaminerich domain.
The interaction between the activation domains and hTAF II 130/dTAF II 110 is functionally important as mutations in the Sp1B activation domain that compromised its ability to interact with the TAF II protein also reduced the ability of Sp1B to activate transcription in vivo (21, 23, 34) . Transient overexpression of the hTAF II 130 central glutamine-rich domain interfered with Sp1-dependent transcription in HeLa cells, suggesting a coactivator role for hTAF II 130.
We have previously identified the regions in hTAF II 130 required for interaction with different activation domains (23) . To further dissect the minimal interaction domain in hTAF II 130, we generated point mutations in the minimal Q1/Q2 domain and tested for their ability to interact with the Sp1B and CREB-N activation domains. This analysis has focused on one particular point mutant F311S, in which the phenylalanine at residue 311 has been changed to serine. Phe 311 is the only aromatic amino acid within the Q1/Q2 domain, and its alteration to serine had the most striking effect on Q1/Q2 function. We show that the F311S mutation abrogated the interaction with Sp1B and CREB-N in the context of the Q1/Q2 or Q1-Q4 domain of hTAF II 130. We also found that hydrophobicity at this residue is important for interaction. Deletion of a 9-amino acid segment containing Phe 311 (residues 310 -318), rich in hydrophobic residues, resulted in a Q1/Q2 mutant severely compromised in Sp1B interaction. Interestingly, this hydrophobic sequence motif is similar to the motifs identified in several glutamine-rich activation domains. Our findings indicate that this sequence motif may act as a protein-protein interface that enables hTAF II 130 to interact with Sp1B and mediate its transcriptional activation.
EXPERIMENTAL PROCEDURES
Construction of hTAF II 130Q1/Q2 Point Mutants-hTAF II 130Q1/Q2 was amplified via PCR using ERO-1 forward primer (5Ј-GATAGGATC-CAGAGCCTGTCCCGGACGCCCA-3Ј) and ERO-2 reverse primer (5Ј-ACGCGTCGACTCACTGGACGCCGGGCGAGCGCT-3Ј). ERO-1 contained a BamHI restriction site (underlined) near its 5Ј end, whereas ERO-2 contained a stop codon (bold type) immediately adjacent to a SalI restriction site (underlined). The resulting PCR product was subcloned into BamHI and SalI restriction sites immediately downstream of the hemagglutinin antigen (HA) epitope tag in pEG202(ϩHA) (23) to form pEG202-hTAF II 130Q1/Q2.
To generate point mutations in Q1/Q2, 20 ng of pEG202-hTAF II 130Q1/Q2 DNA was PCR-amplified in a reaction containing 70 pmol each of ERO-1 forward and ERO-3 reverse (5Ј-ACGCCTCGAGA-ATTCACTGGACGCCGGGCGAGCGCT-3Ј) primers, under conditions that reduced the fidelity of DNA synthesis by Taq polymerase as described (35) , such as decreased dATP concentration relative to other dNTPs and addition of MnCl 2 . The BamHI/XhoI-digested pool of mutated DNA fragments was subcloned into BamHI and SalI sites immediately downstream of the HA tag in pEG202(ϩHA). Recombinant plasmids were individually transformed into yeast strain EGY48 along with the pJG45 plasmid containing the Sp1B or CREB-N activation domain (23) . hTAF II 130 mutants exhibiting increased or decreased interaction with Sp1B or CREB-N (higher or lower ␤-galactosidase activity compared with wild type) were sequenced to determine the mutated residues.
Construction of the pEG202-hTAF II 130 F311I, F331W, and F311Y mutants involved the use of PCR primers that contained codons encoding isoleucine, tryptophan, or tyrosine in place of the phenylalanine. A 150-base pair region containing F311 was PCR-amplified with ERO-1 forward primer and JKO-1 (5Ј-CAGCTGAATATTCTGGATGTTGGTC-GGGTT-3Ј), JKO-2 (5Ј-CAGCTGCCAGTTCTGGATGTTGGTCGGGTT-3Ј), JKO-3 (5Ј-CAGCTGGTAGTTCTGGATGTTGGTCGGGTT-3Ј) reverse primers. Underlined sequences in JKO-1, JKO-2, and JKO-3, respectively encode for isoleucine, tryptophan, and tyrosine substitutions.
To make pEG202-hTAF II 130(⌬9), PCR products from two separate PCR reactions were ligated to create the 9-amino acid deletion and a PvuII site without altering any amino acids. The 5Ј half was amplified with Q1R forward primer (5Ј-GAATTCCAGAGCCTGTCCCGGAC-3Ј) and Q1H1 reverse primer (5Ј-CAGCTGGATGTTGGTCGGGTTC-3Ј); the 3Ј half was amplified with Q1H2 forward primer (5Ј-CAGCTGGTC-CGAAGTGAGAATGGGCA-3Ј) and ERO-3 reverse primer. The Q1R primer contained an EcoRI restriction site, whereas both Q1H1 and Q1H2 primers contained a PvuII restriction site (all sites within primers are underlined). The resulting mutant (⌬9) contained a 9-amino acid deletion (⌬310 -318) and an internal PvuII site.
The pCMV-hTAF II 130 derivatives were constructed by excising the NdeI/SalI fragment containing the hTAF II 130Q1/Q2 or hTAF II 130-(F311S) coding region from the yeast plasmids and subcloning into the NdeI/XhoI sites in the cytomegalovirus-driven mammalian expression plasmid downstream of an HA tag (21) . In the case of pCMVhTAF II 130(⌬9), a DNA fragment amplified with 130Q1Nde forward primer (5Ј-CATATGCAGAGCCTGTCCCGGAC-3Ј) and ERO-3 reverse primer was subcloned into NdeI/XhoI-digested pCMV vector.
Yeast Two-hybrid Analysis-pEG202-hTAF II 130Q1/Q2 derivatives were cotransformed into the yeast strain EGY48 (36) with pJG45-Sp1B (residues 263-542) or CREB-N (residues 3-296) and the LacZ reporter plasmid pSH34 (37) as described (38) . For measurement of quantitative ␤-galactosidase activity, yeast transformants were grown in liquid minimal medium for 36 h at 30°C. Cells were pelleted, washed in 1 ml of galactose/raffinose induction medium, reinoculated with 1 ml of the same medium. ␤-Galactosidase activity was measured in triplicate as described (38) , and protein expression of the fusion proteins was verified by Enhanced Chemiluminescence (Amersham Pharmacia Biotech) with ␣-HA antibody.
Transient Transfection Assay-Nearly confluent HeLa cells were transfected with 4 g of 5xGal4-E1b-Luciferase reporter (39), 1 g of pCMV-LacZ, 2 g of Gal4-Sp1B (34), plus 13 g total of pCMV empty vector and pCMV-hTAF II 130 derivative via electroporation (total DNA, 20 g). HeLa cells were plated on 60-mm dishes prior to the day of transfection. In the Gal4-Q1/Q2 activation experiments, the same amount of 5xG4-E1b-Luc and pCMV-LacZ plasmids were used with 15 g of Gal4-Q1/Q2 construct and pCMV vector. Luciferase activity was quantified as described (23) . All transfections were performed in triplicate at least three times.
In Vitro Protein Binding Assay-DNA fragments containing wild type Q1/Q2, F311S, or ⌬9 were subcloned into a bacterial expression vector pRSETC (Invitrogen) and transformed into Escherichia coli strain BL21 LysS to generate fusion proteins tagged with the bacteriophage T7 gene 10 leader peptide (T7 tag). The recombinant proteins were first immunopurified from soluble lysates using ␣-T7 antibody (Novagen) and protein A-Sepharose and then incubated with wheat germ agglutinin-purified recombinant Sp1 prepared from recombinant vaccinia virus-infected HeLa cells. The Sepharose beads were washed in a buffer containing 25 mM Hepes-KOH, pH 7.9, 0.1 mM EDTA, 12.5 mM MgCl 2 , 0.1M KCl, 20% glycerol, 0.1% Nonidet P-40, and bound proteins were separated by SDS-polyacrylamide gel electrophoresis and analyzed by Western immunoblotting.
RESULTS
The Phenylalanine Residue at Position 311 Is Critical for hTAF II 130 Interaction with Sp1B and CREB-N-We previously observed in yeast two-hybrid interaction assays that the Q1 region of the central domain of hTAF II 130 was sufficient for interaction with the Sp1B activation domain, whereas the Nterminal Q2 activation domain of CREB (CREB-N) exhibited a broader requirement for the Q1/Q2 region of hTAF II 130 (23) . To examine which amino acid residues within the Q1/Q2 domain are important for mediating Sp1B and CREB-N interactions, we constructed a number of Q1/Q2 point mutants and tested them for their ability to interact with Sp1B and CREB-N in yeast two-hybrid assays (Fig. 1) . The resulting hTAF II 130 mutants displayed different interaction patterns with Sp1B and CREB-N (Fig. 1B) , consistent with previous observations suggesting that distinct activation domains target different regions of hTAF II 130 for interaction (23) . One Q1/Q2 mutant of particular interest was the mutant F311S, which has a serine in place of the phenylalanine at residue 311 (Fig. 1A) . This mutant had the most striking phenotype, and the phenylalanine is the only aromatic residue in the entire 150-amino acid stretch of the Q1/Q2 domain. Bulky hydrophobic residues have been shown to be critical for the function of many transcription factors (34, 40 -42) . Our yeast two-hybrid analysis revealed that the F311S mutation decreased the ability of the Q1/Q2 domain to interact with Sp1B and CREB-N as noted by their dramatically reduced ␤-galactosidase activity compared with that of wild type Q1/Q2 (Fig. 1B) . The reduced activity was not due to decreased expression of the mutant protein because its level of expression was comparable with that of the wild type (data not shown). These results suggest that Phe 311 plays an important role in allowing hTAF II 130 to interact with the Sp1B and CREB-N activation domains.
To determine whether the decreased interaction exhibited by the F311S mutation in the Q1/Q2 domain had a similar effect in the context of the larger Q1-Q4 domain, we introduced the same mutation into Q1-Q4, and the resulting mutant Q1-Q4 (F311S) was tested in yeast two-hybrid interaction assays with Sp1B and CREB-N (Fig. 1C) . The Q1-Q4 (F311S) mutant interacted weakly with either Sp1B or CREB-N compared with wild type Q1-Q4, suggesting that the F311S mutation in the context of Q1-Q4 also interferes with the ability of hTAF II 130 to interact with activation domains.
Hydrophobicity at Residue 311 Is an Important Determinant of hTAF II 130-Activator Interaction-To further examine the contribution of the Phe 311 to the ability of hTAF II 130Q1/Q2 to interact with activation domains, additional mutants were generated where the phenylalanine was substituted with other bulky aromatic or hydrophobic residues. Substitution of the phenylalanine with isoleucine (F311I) or tryptophan (F311W) resulted in comparable ␤-galactosidase activity with that of the wild type Q1/Q2 in interaction assays with Sp1B or CREB-N (Fig. 2) . However, when a tyrosine replaced phenylalanine, the ␤-galactosidase activity of the resulting mutant (F311Y) was severely reduced to a level similar to or lower than that of F311S. The expression of all mutant proteins was comparable with that of the wild type (data not shown). These results suggest that the hydrophobicity of the phenylalanine, rather than the amino acid per se, is an important determinant of hTAF II 130 interaction with Sp1B and CREB-N.
To examine the contribution of the sequence surrounding Phe 311 in hTAF II 130, we made a Q1/Q2 derivative (⌬9) lacking 9 residues (310 -318) including F311 and tested its ability to interact with Sp1B in a yeast two-hybrid interaction assay (Fig.  3) . Deletion of this sequence further compromised its ability to interact with Sp1B compared with the point mutant F311S (Fig. 3B) . The reduced interaction was not due to lower protein expression because all derivatives were expressed at similar levels (data not shown). We conclude from these results that this hydrophobic sequence is important in the interaction of hTAF II 130Q1/Q2 with Sp1B.
The F311S and ⌬9 Mutants Show Reduced Interaction with Sp1 in Vitro-To demonstrate using a different assay the interaction between Sp1 and wild type or mutant derivatives of hTAF II 130, we carried out in vitro protein binding assays with the Q1/Q2 derivatives expressed and purified from E. coli. Wild type Q1/Q2, F311S, and ⌬9, each tagged with the bacteriophage T7 gene 10 leader peptide (T7 tag) were immunopurified with ␣-T7 tag antibody and incubated with full-length Sp1 partially purified from the recombinant Sp1 vaccinia virus-infected HeLa cells. Consistent with the yeast two-hybrid results, Sp1 was retained by the wild type Q1/Q2 protein (Fig. 4A, lane 3) but not by the mutant F311S (lane 4) or ⌬9 (lane 5) . The same immunoblot was probed with ␣-T7 antibody to show that equal amounts of the immunopurified Q1/Q2 derivatives were present in the binding reactions (Fig. 4B) . We conclude that F311S and ⌬9 mutants do not interact efficiently with Sp1 in vitro.
The F311S and ⌬9 Mutants Show Reduced Ability to Activate Transcription When Fused to the DNA-binding Domain of
Gal4 -Within the C-terminal half of Sp1B (Sp1B-c), previous studies revealed a hydrophobic "patch" (residues 450 -473; The results of the protein interaction studies suggest that the hydrophobic sequence motif, similar to the one characterized for Sp1B, is important for hTAF II 130 function. Based on these findings, we asked whether this region in hTAF II 130Q1/ Q2 might function as an activation domain when fused to a DNA-binding domain. We constructed fusions between the wild type and mutant Q1/Q2 sequences and the yeast Gal4 DNAbinding domain and tested the fusion proteins for the ability to activate a luciferase reporter gene driven by multiple Gal4-binding sites in HeLa cells by transient transfections (Fig. 6) .
We found Gal4-Q1/Q2 (wild type) activated the reporter ϳ14-fold compared with Gal4 alone. Significantly, Gal4-F311S containing the F311S point mutation in Q1/Q2 activated ϳ11-fold and Gal4-⌬9 containing the 9-amino acid deletion ϳ4-fold. Because increasing the amount of the transfected DNA encoding the Gal4 derivatives did not significantly alter fold activation for each derivative, we think the Gal4-binding sites in the reporter plasmid are fully occupied in the transfected cells under these conditions. The relative ability to activate transcription by the Gal4-Q1/Q2 derivatives was similar to their was co-transformed with pJG45-Sp1B as described in Fig. 1 . The ␤-galactosidase activity is displayed relative to wild type Q1/Q2 (set to 100%). The low level activity detected in the ⌬9 mutant is indistinguishable from the background level of the assay. ability to interact with Sp1B, although the F311S mutant was considerably more active in this assay. Because Gal4-⌬9 demonstrated a moderate ability to activate compared with Gal4 alone (ϳ4-fold), we conclude that the ⌬9 mutant protein has maintained its structural integrity despite the deletion of 9 residues. These findings suggest that residues 310 -318 play a role in the activation of hTAF II 130Q1/Q2 when fused to a DNA-binding domain.
The F311S and ⌬9 Mutations Reduce the Ability of hTAF II 130Q1/Q2 to Function as a Dominant Negative of Sp1B-mediated Transcription in Vivo-
We previously demonstrated that overexpression of Q1/Q2 or Q1-Q4 derivatives of hTAF II 130 inhibited Sp1-mediated but not VP16-mediated transcription in HeLa cells (23) . The inhibition was specific to the central Q-rich domains because overexpression of an Nterminal derivative of hTAF II 130 had no effect. We next examined whether the introduction of either the F311S or ⌬9 mutation would affect the ability of the Q1/Q2 domain to inhibit Sp1B-dependent activation in vivo. Because F311S and ⌬9 mutants interacted poorly with Sp1B, we expected these mutants to be less effective inhibitors of Gal4-Sp1B mediated activation. To examine the effect of wild type or mutant Q1/Q2 domains on transcription by Gal4-Sp1B, a mammalian expression vector carrying either Q1/Q2, F311S, or ⌬9, along with a Gal4-driven luciferase reporter and a Gal4-Sp1B expression plasmid were cotransfected into HeLa cells (Fig. 7) . Overexpression of wild type Q1/Q2 inhibited activation by Gal4-Sp1B in a dose-dependent manner. By comparison, the F311S mutant was less effective at inhibiting transcription by Gal4-Sp1B because more F311S protein was needed to reduce transcription to the same level as the wild type Q1/Q2 protein. Finally, the ⌬9 protein was an even less effective dominant negative; increasing the ⌬9 protein expression had little effect on the activation by Gal4-Sp1B. In these experiments the amount of DNA transfected for each Q1/Q2 derivative was adjusted to produce a comparable range in protein expression (data not shown). A similar analysis was carried out with the ⌬9 mutation introduced into Q1-Q4 (data not shown). We found that Q1-Q4 (⌬9) was also compromised in its ability to inhibit activation by Gal4-Sp1B compared with the wild type Q1-Q4. Again, more Q1-Q4 (⌬9) protein was required to achieve a comparable level of reduction in the reporter activity as the wild type protein. We deduce from these findings that residues 310 -318 in hTAF II 130 play an important role in interacting with Sp1B and mediating Sp1B-dependent activation in vivo.
DISCUSSION
Mutational analysis of many acidic and glutamine-rich activation domains have demonstrated the importance of hydrophobic residues in mediating protein-protein interactions and transcriptional activation (34, 40, 41, (43) (44) (45) (46) . Often, alteration of a single bulky hydrophobic amino acid is enough to produce deleterious effects (34, 40 -42) . In our TAF II -activator interaction experiments, we found that mutation of F311 (only aromatic residue within the 150-amino acid Q1/Q2 domain) into a serine dramatically reduced the interaction of Q1/Q2 with (34) . The dotted underline in Sp1B represents the region altered in the M37 linker insertion mutant (34) . Deletion of the dotted underlined region in CREB-Q2 (residues 204 -213) abrogated its interaction with dTAF II 110 (24) . The underlined sequence in Oct 2 represents the Q 18 III amino acid segment that displays a potent activation function when reiterated (47) . Alignment of Sp1B, Sp1A, and CREB is adapted from Ref. 34 . Amino acids within the core consensus are shaded in black; those identical to hTAF II 130 are shaded in gray. The consensus core sequence is XQ(L/T)(P/L) where X represents a bulky hydrophobic amino acid.
FIG. 6.
The ⌬9 mutant is a weak transcriptional activator when fused to the Gal4 DNA-binding domain. HeLa cells were cotransfected with increasing amounts (0.5, 1.0, and 2.5 g of DNA) of the Gal4 DNA-binding domain fused to wild type Q1/Q2, F311S, or ⌬9 along with the 5xGal4-E1b-Luciferase reporter construct, and the luciferase activity was measured from whole cell lysates. The ␤-galactosidase activity measured from the cotransfected lacZ plasmid was similar in all samples, suggesting comparable transfection efficiency (data not shown). All transfections were done in triplicate. Sp1B and CREB-N. Deletion of 9 residues from Q1/Q2 including Phe 311 further reduced its interaction with the activation domains and interfered with the ability of Q1/Q2 to function as a dominant negative of Sp1B-mediated transcriptional activation.
We aligned Phe 311 in Q1/Q2 to the tryptophan residue (Trp 457 ) in Sp1B as well as to the bulky hydrophobic residues in Sp1A and CREB and found some common features among these sequences (Fig. 5) . Trp 457 was previously shown to be important for the interaction of the C-terminal half of Sp1B (Sp1B-c) with dTAF II 110 and transcriptional activation by Sp1B-c (34) . Insertion of a linker sequence in place of residues 455-465 in Sp1B-c (mutant M37) produced effects similar to the Trp 3 Ala mutation at residue 457. This finding suggested that an alternating hydrophobic and polar amino acid sequence motif in Sp1B-c including Trp 457 ("hydrophobic patch") represents an interaction surface between an activator (Sp1B-c) and its target coactivator (dTAF II 110) (34) . Interestingly, similar hydrophobic motifs are present in the CREB N-terminal Q2 and Sp1A activation domains, both of which interact with dTAF II 110 and hTAF II 130 (Ref. 34 and Fig. 5 ). In the case of CREB-Q2, deletion of 10 amino acids including this motif (⌬204 -213) significantly reduced its interaction with dTAF II 110 (24) . We also found a similar motif in the glutaminerich activation domain of Oct 2 within the 18-amino acid QIII segment (Fig. 5 ) that when reiterated displays a potent activation function (47) . The activation domain of the CCAAT-binding factor CBF-B also resembles that of Sp1 (48), and significantly, CBF has been shown to interact with dTAF II 110 (25) . As for the TAF II s related to hTAF II 130, we found putative hydrophobic patches in dTAF II 110 and hTAF II 105, a B-cell specific human TAF II closely related to hTAF II 130 (49) , and aligned them with that of hTAF II 130 (Fig. 5) . The N-terminal 308 residues of dTAF II 110 that include this hydrophobic patch have been shown to be sufficient to interact with Sp1A (22) . Alignment of TAF II s and their target transcriptional activation domains reveals a consensus core sequence of XQ(L/T)(P/L), where X represents a bulky hydrophobic amino acid. Thus, similar sequence motifs identified in the glutamine-rich activation domains and TAF II s appear to play essential roles in the function of both classes of transcription factors.
Consistent with this analysis we found that the Q1/Q2 domain of hTAF II 130 fused to the Gal4 DNA-binding domain activates transcription in transfected HeLa cells (Fig. 6) . Furthermore, mutations (F311S and ⌬9) that affect interaction with activation domains also reduced the potency of activation by Gal4-Q1/Q2. Thus, the sequence motif important for Q1/Q2 function represents a protein-protein interaction surface similar to ones present in certain activation domains.
It is conceivable that Sp1B and hTAF II 130 contact each other through these shared hydrophobic sequence motifs; however, additional pocket-like surfaces in each protein may be involved in the interaction with the hydrophobic motif. An example of a protein pair making hydrophobic contacts is found in the crystal structure of the MDM2 oncoprotein complexed with a p53 activation domain peptide (50) . The study reveals the p53 ␣ helix forming a structure highly complementary to the hydrophobic pocket of MDM2, filling up the space within the pocket. The primary contacts with the MDM2 pocket are made by three hydrophobic and aromatic amino acids on the hydrophobic face of the p53 ␣ helix. Because the same sequence of p53 is implicated in binding to the hTAF II 31/hTAF II 70 complex (51, 52) , similar interactions involving hydrophobic residues are likely to occur between p53 and its target TAF II . It is possible that hTAF II 130 may interact with its target activation domain in a similar manner that involves contacts made by the hydrophobic residues. Secondary structure prediction algorithms suggest incorporation of some of the residues within the hTAF II 130 hydrophobic motif into short ␤-sheets. The hydrophobic segment may further adopt an ordered secondary structure upon contact with the target activation domain.
Characterization of another TAF II -activator interaction surface was recently reported for hTAF II 55 and the ligand-binding domain of certain nuclear receptors (53) . The study shows that hTAF II 55 interacts with and modulates activation through a 40-amino acid region of the vitamin D 3 and thyroid hormone receptor ligand-binding domain but not through a highly related region that is also present in the retinoid X receptor, suggesting that subtle differences in the target sequence influence the specificity of interaction.
Solution structure of an activator-coactivator complex has been reported for the activation domain of VP16 bound to hTAF II 31 (54) , and the kinase-inducible domain of CREB bound to the KIX domain of CBP (55) . Both studies found that the activation domain undergoes a transition from a random coil to ␣ helix upon binding to the target coactivator protein. It should be noted that transcriptional activation by CREB requires two distinct activator-coactivator interactions: the interaction between the kinase-inducible domain of CREB and CBP and the interaction between the Q2 activation domain of CREB and hTAF II 130 (56) . The induced conformational change in the neighboring kinase-inducible domain upon contact with CBP will likely influence the interaction between Q2 and hTAF II 130. It remains to be seen whether Sp1B-c and CREB-Q2 undergo similar conformational changes upon binding to hTAF II 130. Molecular analysis of the hTAF II 130-activator interface should facilitate structural characterization of these important activator-coactivator complexes and understanding of the mechanisms underlying transcriptional activation.
